Last reviewed · How we verify
Daclatasvir and Asunaprevir
Daclatasvir and Asunaprevir are direct-acting antivirals that inhibit the HCV NS5A and NS3/4A proteases, respectively.
Daclatasvir and Asunaprevir are direct-acting antivirals that inhibit the HCV NS5A and NS3/4A proteases, respectively. Used for Chronic hepatitis C virus (HCV) infection, genotype 1b.
At a glance
| Generic name | Daclatasvir and Asunaprevir |
|---|---|
| Also known as | Daclatasvir and Asunaprevir combined treatment for 24 weeks |
| Sponsor | Sang Gyune Kim |
| Drug class | Direct-acting antiviral |
| Target | HCV NS5A, HCV NS3/4A protease |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 2 |
Mechanism of action
Daclatasvir targets the NS5A protein, which is essential for viral replication and assembly, while Asunaprevir targets the NS3/4A protease, which is involved in the processing of viral proteins. By inhibiting these enzymes, Daclatasvir and Asunaprevir prevent the replication of the hepatitis C virus.
Approved indications
- Chronic hepatitis C virus (HCV) infection, genotype 1b
Common side effects
- Fatigue
- Nausea
- Diarrhea
- Headache
- Anemia
Key clinical trials
- Early Post-marketing Study of Daclatasvir (Daklinza®) + Asunaprevir (Sunvepra®) in the Treatment of Chronic Hepatitis C (CHC) in Adults
- Real-world Incidence Proportion of Hepatic Toxicity and All Adverse Drug Reactions (ADRs) in Japanese Patients Receiving Daclatasvir (DCV) Trio Therapy
- Postmarketing Surveillance of the Safety and Effectiveness of Daclatasvir and Asunaprevir for the Treatment of Chronic HCV Genotype 1B Infection in the Routine Clinical Practice in Korea
- Effectiveness and Safety of Direct-Acting Antiviral Agents for the Treatment of Chronic Hepatitis C
- Phase III China GT 1b Interferon (IFN) Intolerant Prev Exclude Dual (PHASE3)
- Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study) (PHASE2)
- Triple or Quadruple Combination DAAs Treatment for Subjects With HCV GT 1b Infection (PHASE2)
- Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Daclatasvir and Asunaprevir CI brief — competitive landscape report
- Daclatasvir and Asunaprevir updates RSS · CI watch RSS
- Sang Gyune Kim portfolio CI